tbuckley/cabot-search huggingface dataset:
Pityrosporum Ovale and Some Scaly Conditions of the Scalp
Authors: F. A. Whitlock
Journal: BMJ (1953)

DRUG TREATMENT FOR THYROTOXICOSIS MICL JOURNAL patients who do not desire surgery and cannot have radioiodine, and is used with many other patients for varying reasons.We would suggest that the procedure outlined above, while simplifying the management of such cases, diminishes the risk of goitrogenesis and of worsening of the eye signs without impairing the therapeutic effects.tWe should expect the procedure to be similarly suitable for preparing the thyrotoxic patient for operation, provided iodide is given in addition over the last two weeks.We are at present investigating the latter method.Summary A preliminary report is-made of the practicability of treating thyrotoxicosis with both methylthiouracil and thyroxine to simplify the control of dosage.The results were apparently as satisfactory as the published results obtained with antithyroid drugs alone.A basic standard dosage was used (enough methyl- thiouracil to control all but exceptional thyrotoxicosis and the minimal normal thyroxine requirements-that is, methylthiouracil, 50 mg., and L-thyroxine, 1 mg., thrice daily); this standard dosage, unaltered, suffices for the maintenance treatment of most patients, provided signs of goitre enlargement are sought and when seen are countered by giving additional thyroxine.If the adequacy of the control of thyrotoxicosis is doubted the methylthiouracil dose can be increased.Among the first 32 cases completing a course of nine or more months of such treatment, in 18 (56%) the thyrotoxicosis was still fully re:mitted one year later, in no case had the eye signs significantly worsened, and in all except one the goitre size had decreased.We are indebted to Glaxo Laboratories Ltd., who supplied the pills for this trial.
Changing the Terminology of Cancer—Reply
Authors: Laura J. Esserman, Ian M. Thompson, Brian J. Reid
Journal: JAMA (2014)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Stimulatory Effect of Pseudomonas aeruginosa on Mucin Secretion by the Respiratory Epithelium
Authors: Kenneth B. Adler
Journal: JAMA (1983)

Cell-free filtrates of broth cultures from 11 of 18 strains of Pseudomonas aeruginosa isolated from patients with cystic fibrosis (CF) (or from patients without CF) increased substantially the secretion of mucin by explants of trachea from guinea pigs and human tracheal tissue obtained at autopsy. The effect was not related to the mucoid nature of the isolates, was not destroyed by heating at 90 degrees C for 30 minutes, and was not dependent on serotype. As P aeruginosa commonly infects the respiratory tracts of persons with CF, elaboration of an extracellular product that stimulates mucin secretion could play a role in the pathogenesis of the disease in the airways.
Elastographie quantitative ou élastométrie guidée par échoendoscopie (EE). Résultats d'une étude pilote chez 86 patients
Authors: M Giovannini, E Bories, C Pesenti, F Caillol, G Monges, JR Delpero
Journal: Endoscopy (2008)

Introduction: L'élastographie est une nouvelle technologie dans laquelle les modifications de contrainte des tissus sont employées pour détecter des tumeurs. Une tumeur cancéreuse est normalement 5–10 fois plus «rigide» que le tissu normal. Quand une compression mécanique est appliquée, la tumeur se déforme moins que le tissu environnant c.-à-d. La contrainte dans la tumeur est moindre que dans le tissu environnant. Cette propriété produit des images remarquablement claires. Néanmoins, le degré de compression pouvait entrainer d'importantes variations des images obtenues. La mise au point d'un software de 2ème génération permet d'obtenir une quantification de l'élasticité du tissu étudié par rapport à un tissu de référence. Le but de cette étude a été d'appliquer cette 2ème génération d'élastographie à l'échoendoscopie pour caractériser les masses pancréatiques et les adénopathies.
Serpent and Quill
Authors: Wilder Penfield
Journal: New England Journal of Medicine (1962)

WE celebrate tonight a very happy occasion, the hundred and fiftieth anniversary of the birth of the New England Journal of Medicine. I rejoice that it should fall to me to bring felicitations and congratulations in the name of physicians in this country and Canada, and indeed of all the English-speaking world, to this journal on its hundred and fiftieth birthday, its Sesquicentennial Anniversary. Believing that the Journal has a corporate consciousness, I should like to address it directly. Here is a tribute of admiration for your discriminating conservatism, gratitude for the excellence of your literary standards and . . .
Mitochondrial Encephalomyopathy Due to a Novel Mutation in<i>ACAD9</i>
Authors: Caterina Garone, Maria Alice Donati, Michele Sacchini, Beatriz Garcia-Diaz, Claudio Bruno, Sarah Calvo, Vamsi K. Mootha, Salvatore DiMauro
Journal: JAMA Neurology (2013)

<h3>Importance</h3> Mendelian forms of complex I deficiency are usually associated with fatal infantile encephalomyopathy. Application of "MitoExome" sequencing (deep sequencing of the entire mitochondrial genome and the coding exons of &gt;1000 nuclear genes encoding the mitochondrial proteome) allowed us to reveal an unusual clinical variant of complex I deficiency due to a novel homozygous mutation in<i>ACAD9</i>. The patient had an infantile-onset but slowly progressive encephalomyopathy and responded favorably to riboflavin therapy. <h3>Observation</h3> A 13-year-old boy had exercise intolerance, weakness, and mild psychomotor delay. Muscle histochemistry showed mitochondrial proliferation, and biochemical analysis revealed severe complex I deficiency (15% of normal). The level of complex I holoprotein was reduced as determined by use of Western blot both in muscle (54%) and in fibroblasts (57%). <h3>Conclusions and Relevance</h3> The clinical presentation of complex I deficiency due<i>ACAD9</i>mutations spans from fatal infantile encephalocardiomyopathy to mild encephalomyopathy. Our data support the notion that ACAD9 functions as a complex I assembly protein. ACAD9 is a flavin adenine dinucleotide–containing flavoprotein, and treatment with riboflavin is advisable.
Funding of drugs: do vaccines warrant a different approach?
Authors: Philippe Beutels, Paul A Scuffham, C Raina MacIntyre
Journal: The Lancet Infectious Diseases (2008)

Vaccines have features that require special consideration when assessing their cost-effectiveness. These features are related to herd immunity, quality-of-life losses in young children, parental care and work loss, time preference, uncertainty, eradication, macroeconomics, and tiered pricing. Advisory committees on public funding for vaccines, or for pharmaceuticals in general, should be knowledgable about these special features. We discuss key issues and difficulties in decision making for vaccines against rotavirus, human papillomavirus, varicella-zoster virus, influenza virus, and Streptococcus pneumoniae. We argue that guidelines for economic evaluation should be reconsidered generally to recommend (1) modelling options for the assessment of interventions against infectious diseases; (2) a wider perspective to account for impacts on third parties, if relevant; (3) a wider scope of costs than health-care system costs alone, if appropriate; and (4) alternative discounting techniques to explore social time preference over long periods.
Suprasellar Aneurysm An Unusual Cause of Hypopituitarism
Authors: Vanghibhuram V. Shantharam
Journal: JAMA (1974)

PANHYPOPITUITARISM, an uncommon clinical disorder, may result from a variety of underlying conditions. Chromophobe adenoma is perhaps the most frequent precipitating cause. Less common but confirmed causes include postpartum pituitary infarction, granulomatous disorders, head trauma, hemorrhage, suprasellar cyst, craniopharyngioma, and suprasellar aneurysm, which is presented here.  Report of a Case  A 55-year-old white woman was hospitalized because of a visual field defect. Additional complaints were bifrontal headache, 18-kg (40-lb) weight loss, alopecia, cold sensitivity, and increased sleep requirements. She denied having polydipsia, polyuria, or nocturia. She had been hypertensive for many years but had remained normotensive in the last 18 months without therapy. Her pregnancies had been uncomplicated, and she had reached an uneventful menopause at age 50 years.  Vital signs were normal. The optic fundi showed mild congestion of retinal vessels but no papilledema, hemorrhage, or exudates. Visual field examination by perimetry showed a bitemporal hemianopsia. Axillary hair was
Handbook of Pain Relief in Older Adults: An Evidence-Based Approach
Authors: Matthias Karst
Journal: JAMA (2011)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Out-of-Hospital Cardiac Arrest in the 1990s: A Population-Based Study in the Maastricht Area on Incidence, Characteristics and Survival
Authors: Jacqueline J.M de Vreede-Swagemakers, Anton P.M Gorgels, Willy I Dubois-Arbouw, Jan W van Ree, Mat J.A.P Daemen, Leon G.E Houben, Hein J.J Wellens
Journal: Journal of the American College of Cardiology (1997)
Detection of autosomal dominant polycystic kidney disease by NMR spectroscopic fingerprinting of urine
Authors: Wolfram Gronwald, Matthias S. Klein, Raoul Zeltner, Bernd-Detlef Schulze, Stephan W. Reinhold, Markus Deutschmann, Ann-Kathrin Immervoll, Carsten A. Böger, Bernhard Banas, Kai-Uwe Eckardt, Peter J. Oefner
Journal: Kidney International (2011)
PROGRESSIVE HYPONATREMIA DURING HEART FAILURE TREATMENT PROVIDES ADDITIONAL LONG-TERM PROGNOSTIC INFORMATION TO HEMOCONCENTRATION IN PATIENTS ADMITTED WITH ACUTE DECOMPENSATED HEART FAILURE
Authors: Takahisa Yamada, Takashi Morita, Yoshio Furukawa, Shunsuke Tamaki, Yusuke Iwasaki, Masato Kawasaki, Atsushi Kikuchi, Takumi Kondo, Tsutomu Kawai, Satoshi Takahashi, Masashi Ishimi, Hideyuki Hakui, Tatsuhisa Ozaki, Yoshihiro Satoh, Masahiro Seo, Masatake Fukunami
Journal: Journal of the American College of Cardiology (2015)
OPTIMIZING MONOCLONAL ANTIBODY (CYT-356) IMAGING IN PATIENTS WITH PROSTATE CANCER
Authors: L. R. Witherspoon, C. Neal, S. E. Shuler, S. F. Bardot, B. H. Bodie, A. Sardi, R. Gaudin
Journal: Clinical Nuclear Medicine (1993)

Witherspoon, L. R.; Neal, C.; Shuler, S. E.; Bardot, S. F.; Bodie, B. H.; Sardi, A.; Gaudin, R. Author Information
Survival and Outcomes Following Bioprosthetic vs Mechanical Mitral Valve Replacement in Patients Aged 50 to 69 Years
Authors: Joanna Chikwe, Yuting P. Chiang, Natalia N. Egorova, Shinobu Itagaki, David H. Adams
Journal: JAMA (2015)

<h3>Importance</h3> In nonelderly patients with mitral disease requiring valve replacement, deciding between bioprosthetic and mechanical prosthetic valves is challenging because long-term survival and morbidity are not well defined. <h3>Objective</h3> To quantify survival and major morbidity after mitral valve replacement in patients aged 50 to 69 years. <h3>Design, Setting, and Participants</h3> Retrospective cohort analysis of 3433 patients (aged 50-69 years) who underwent primary, isolated mitral valve replacement in New York State hospitals from 1997-2007. Follow-up ended November 30, 2013; median duration was 8.2 years (range, 0-16.8 years). Propensity score matching for 19 baseline characteristics yielded 664 patient pairs. <h3>Exposures</h3> Bioprosthetic vs mechanical prosthetic mitral valve replacement. <h3>Main Outcomes and Measures</h3> All-cause mortality, stroke, reoperation, and major bleeding events. <h3>Results</h3> No survival difference was observed between use of mechanical prosthetic and bioprosthetic mitral valves in patients aged 50 to 69 years matched by propensity score (209 and 221 deaths, respectively), or in a subgroup analysis of age by decade. Actuarial 15-year survival was 57.5% (95% CI, 50.5%-64.4%) after mechanical replacement vs 59.9% (95% CI, 54.8%-65.0%) after bioprosthetic valve replacement (hazard ratio [HR], 0.95 [95% CI, 0.79-1.15],<i>P</i> = .62). The 15-year cumulative incidence of stroke was higher after mechanical (65 strokes; 14.0% [95% CI, 9.5%-18.6%]) vs bioprosthetic valve replacement (41 strokes; 6.8% [95% CI, 4.5%-8.8%]) (HR, 1.62; 95% CI, 1.10-2.39). The 15-year cumulative incidence of reoperation was lower for mechanical (28 reoperations; 5.0% [95% CI, 3.1%-6.9%]) compared with bioprosthetic (47 reoperations; 11.1% [95% CI, 7.6%-14.6%]) valves (HR, 0.59; 95% CI, 0.37-0.94). The 15-year cumulative incidence of a bleeding event was higher for mechanical (72 events; 14.9% [95% CI, 11.0%-18.7%) vs bioprosthetic (49 events; 9.0% [95% CI, 6.4%-11.5%]) valves (HR, 1.50; 95% CI, 1.05-2.16). <h3>Conclusions and Relevance</h3> Among patients aged 50 to 69 years undergoing mitral valve replacement in New York State, there was no significant survival difference at 15 years in patients matched by propensity score who underwent mechanical prosthetic vs bioprosthetic mitral valve replacement. Mechanical prosthetic valves were associated with lower risk of reoperation but greater risk of bleeding and stroke. Even though these findings suggest bioprosthetic mitral valve replacement may be a reasonable alternative to mechanical prosthetic valve replacement in patients aged 50 to 69 years, the 15-year follow-up was insufficient to fully assess lifetime risks, particularly of reoperation.
Self harm in young people
Authors: A. House
Journal: BMJ (2014)

Much of what is known about non-fatal self harm and its outcomes is derived from research in people who have presented to hospital for physical treatment immediately after an act; few community based longitudinal studies exist. This is unfortunate because many episodes of self harm—especially those concerning young people—do not lead to hospital presentation. The linked paper (doi:10.1136/bmj.g5954) by Mars and colleagues based on the Avon Longitudinal Study of Parents and Children (ALSPAC) birth cohort is therefore welcome, offering a rare five year follow-up of young people between the ages of 16 and 21 years. Suicide is rare in adolescence, and over time non-fatal acts tend to decrease in frequency—both findings endorsed by Mars and colleagues’ study. Otherwise the news is not so good. At follow-up those who reported self harm at any age up to 16 years Much of what is known about non-fatal self harm and its outcomes is derived from research in people who have presented to hospital for physical treatment immediately after an act; few community based longitudinal studies exist. This is unfortunate because many episodes of self harm—especially those concerning young people—do not lead to hospital presentation. The linked paper (doi:10.1136/bmj.g5954) by Mars and colleagues based on the Avon Longitudinal Study of Parents and Children (ALSPAC) birth cohort is therefore welcome, offering a rare five year follow-up of young people between the ages of 16 and 21 years. Suicide is rare in adolescence, and over time non-fatal acts tend to decrease in frequency—both findings endorsed by Mars and colleagues’ study. Otherwise the news is not so good. At follow-up those who reported self harm at any age up to 16 years Much of what is known about non-fatal self harm and its outcomes is derived from research in people who have presented to hospital for physical treatment immediately after an act; few community based longitudinal studies exist. This is unfortunate because many episodes of self harm—especially those concerning young people—do not lead to hospital presentation. The linked paper (doi:10.1136/bmj.g5954) by Mars and colleagues based on the Avon Longitudinal Study of Parents and Children (ALSPAC) birth cohort is therefore welcome, offering a rare five year follow-up of young people between the ages of 16 and 21 years. Suicide is rare in adolescence, and over time non-fatal acts tend to decrease in frequency—both findings endorsed by Mars and colleagues’ study. Otherwise the news is not so good. At follow-up those who reported self harm at any age up to 16 years were substantially more likely than those with no history of self harm to report repeated acts of self harm; to have current mental health problems (mainly depression and anxiety), difficulties with substance misuse, and lower levels of educational attainment; and were also less.... Language: en
Peripelvic Renal Mass
Authors: Robert J. Cihak
Journal: JAMA (1969)

Dr. James W. Wallace: This 65-year-old man noted intermittent, initial hematuria. He had had gout for many years. At the time of physical examination, evidence of gout was noted, and the prostate gland was moderately enlarged. The urine contained a few erythrocytes and a few leukocytes. Hemoglobin level was 15 gm/100 cc, and white blood cell count was normal. <h3>Discussion</h3> Dr. Laurence L. Robbins: Would you discuss this case, Dr. Nebesar. Dr. Robert A. Nebesar: Several pyelograms have been done over the past six years. On the pyelogram done six years ago, the right kidney looks normal, but the left shows displacement of the upper and middle calices around a central mass (Fig 1). The ureters are normal. The filled bladder shows impression from an enlarged prostate gland. Dr. Wallace: After this first examination, prostatectomy was performed for benign hyperplasia. The most recent examination was done because of persistent left
Identification and functional characterization of a novel 27-bp deletion in the macroglycopeptide-coding region of the GPIBA gene resulting in platelet-type von Willebrand disease
Authors: Maha Othman, Colleen Notley, Frances Louise Lavender, Helen White, Christopher D. Byrne, David Lillicrap, Denise Frances O'Shaughnessy
Journal: Blood (2005)
Radiculopathy associated with disc herniation
Authors: P Goupille
Journal: Annals of the Rheumatic Diseases (2006)

Should we treat it with anti-TNFα agents or is TNFα only one piece of the puzzle?

The treatment of radiculopathy associated with disc herniation by anti-tumour necrosis factor α (TNFα) agents is currently being examined.1–3 However, although the rationale appears to be sound, there is no proof of the efficacy of such a treatment and its use still has not been validated.

Since 1934, when a link was demonstrated between disc herniation and sciatica,4 it has been accepted that compression of the nerve root by disc herniation explained the sciatica. Surgical treatment therefore became standard when medical treatment failed. It now seems that “chemical” factors have a central role in sciatica.

The clinical arguments supporting the “chemical” theory are numerous. Laminectomy is sometimes ineffective, the long term success rate being 40–80%,5 and reintervention rates are reported to be 5–25%.6 A considerable amount of asymptomatic disc herniation7 and severe sciatica without visible root compression has been reported8; there is poor correlation between the severity of symptoms and the extent of the disc herniation9; and the outcome, frequently favourable, is similar after conservative and surgical treatment.10,11

“Chemical factors may play a part in sciatica” 

The role of a chemical component is supported by experimental findings. The spontaneous resorption of disc herniation, dependent on metalloproteinases and neo-vascularisation12 and demonstrated by longitudinal computed tomography and magnetic resonance imaging (MRI) studies, appears to be more marked for large or extruded herniation.13 Immunogenicity of intervertebral discs has been proposed,14 and the nucleus pulposus (NP), isolated from the immune system after its embryological formation, might secrete substances which can induce an autoimmune reaction in cases of disc herniation, particularly those that are extruded.14 Mediators of inflammation and metalloproteinases have been identified …